Clinicopathological features and therapies of elderly women with triplenegative breast cancer

doi:0.3760/cma.j.issn.1673-422X.2013.12.013

Abstract

Abstract: Triplenegative breast cancer (TNBC) in elderly patients presents distinctive clinicopathologic characteristics of large volume and histological grade Ⅲ, and it is seen most frequently in invasive ductal carcinoma, adenocarcinoma and lobular carcinoma. Elderly women with TNBC significantly benefit from adjuvant chemotherapy. But older women frequently have concurrent disease, so neoplasm staging, function of vital organs and tolerance of patient should be considered when treatment programs are selected．The prognosis of older TNBC patient is worse, but rational therapy can improve outcomes significantly.

Key words: Pathology, clinical, Aged, Therapy, Breast neoplasms

GAO Jing. Clinicopathological features and therapies of elderly women with triplenegative breast cancer[J]. Journal of International Oncology, 2013, 40(12): 921-923.

References

［1］ ReisFilho JS, Tutt AN. Triple negative tumours: a critical review. Histopatholog, 2008, 52(1): 108118. ［2］陈欣, 马睿锐, 周文斌, 等. 不同分子亚型老年性乳腺癌的临床病理特征与预后的相关性. 江苏医药, 2011, 37（13）: 1554. ［3］ Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph nodepositive breast cancer. JAMA, 2005, 293(9): 10731081. ［4］ Kang SP, Martel M, Harris LN. Triple negative breast cancer: current understangding of biology and treatment options. Curr Opin Obster Gynecol, 2008, 20(1): 4046. ［5］ Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)negative, and HER2negative invasive breast cancer, the socalled triplenegative phenotype: a populationbased study from the California cancer Registry. Cancer, 2007, 109(9): 17211728. ［6］ Yu KD, Li JJ, Di GH, et al. A straightforward but not piecewise relationship between age and lymph node status in Chinese breast cancer patients. PLoS One, 2010, 5(6): e11035. ［7］ Knigsberg R, Pfeiler G, Klement T, et al. Tumor characteristics and recurrence patterns in triplenegative breast cancer: a comparison between younger(＜65) and elderly (≥65) patients. Eur J Cancer, 2012, 48(16): 29622968. ［8］陆辉, 王水, 夏添松, 等. 240例乳腺癌组织中p53、cerbB2表达的临床分析. 江苏医药, 2007, 33(8): 790791. ［9］ Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 2007, 7: 134. ［10］ Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/ basallike breast carcinomas. Breast Cancer Res, 2007, 9(5): R65. ［11］张萍，徐兵河，马飞，等. 老年三阴性乳腺癌临床病理特征及预后分析. 中国肿瘤临床与康复, 2010, 17(5): 390393. ［12］王琢，王丽娟，张颖超，等. 老年三阴型乳腺癌患者和青年患者临床生物学特征对比. 中国老年学杂志, 2013, 33(3): 694695. ［13］ Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol, 2012, 13: e148160. ［14］ Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol, 2007, 8(12): 11011115. ［15］ Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with earlystage breast cancer. N Engl J Med, 2009, 360（20）: 20552065. ［16］ Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptornegative breast cancer: assessing outcome in a populationbased, observational cohort. J Clin Oncol, 2006, 24(18): 27572764. ［17］ Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol, 2006, 24（18）: 27502756. ［18］ Fargeot P, Bonneterre J, Roche H, et al. Diseasefree survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, nodepositive, elderly breast cancer patients: 6year followup results of the French adjuvant study group 08 trial. J Clin Oncol, 2004, 22（23）: 46224630. ［19］ Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol, 2007, 25（25）: 38083815. ［20］ Alessandra G， Maria PS， Paolo P， et al．HER2 status and eficacy of adjuvant anthracyclines in eady breast cancer: a pooled analysis of randomized trials． J Nad Cancer Inst， 2008， 100（1）: 1420. ［21］ Feher O, Vodvarka P, Jassem J, et al. Firstline gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase Ⅲ study. Ann Oncol, 2005, 16（6）: 899908. ［22］ Aapro M, BernardMarty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol, 2011, 22（2）: 257267. ［23］ Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol, 2005, 23（10）: 21552161. ［24］ Blum JL, Kohles J, McKenna E, et al. Association of age and overall survival in capecitabinetreated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat, 2011, 125(2): 431439. ［25］ Mikhail SE, Sun JF, Marshall JL. Safety of capecitabine: a review. Expert Opin Drug Saf, 2010, 9（5）: 831841. ［26］ Colleoni M, Orlando L, Sanna G, et al. Metronomic lowdose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol, 2006, 17（2）: 232238. ［27］ Salem DA, Gado NM, Abdelaziz NN, et al. Phase Ⅱ trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer. J Egypt Natl Canc Inst, 2008, 20（2）: 134140. ［28］ Biganzoli L, Di Vincenzo E, Jiang Z, et al. Firstline bevacizumabcontaining therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study. Ann Oncol, 2012, 23（1）: 111118. ［29］ Smith IE, Pierga JY, Biganzoli L, et al. Firstline bevacizumab plus taxanebased chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an openlabel study in 2,251 patients. Ann Oncol, 2011, 22（3）: 595602.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.